FLT3 inhibitor BMF-500

{
  "id": "MLC-T-ONC-013626",
  "term": "FLT3 inhibitor BMF-500",
  "field": "Oncology and biomedicine",
  "definition": "An orally bioavailable, covalent and selective inhibitor of FMS-like tyrosine kinase 3 (FLT3; CD135; STK1; FLK2), with potential antineoplastic activity. Upon oral administration, FLT3 inhibitor BMF-500 selectively targets and irreversibly binds to a reactive cysteine in the active site of FLT3. This inhibits the activity of FLT3 and prevents FLT3-mediated downstream signaling. This inhibits the proliferation of FLT3-expressing cancer cells. FLT3, a class III receptor tyrosine kinase (RTK), is overexpressed or mutated in most B-lineage neoplasms and in acute myeloid leukemias.",
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/flt3-inhibitor-bmf-500/"
}